Goal: To review the literature on the significance, risk factors, and management of occult and gross gastrointestinal (GI) bleeding in patients on antiplatelets and/or anticoagulants.
G astrointestinal (GI) bleeding is a common and significant medical problem. Mortality from upper gastrointestinal (UGI) and lower gastrointestinal (LGI) bleeding rates at 3.5% to 13% and 1% to 5%, respectively. [1] [2] [3] In addition, GI bleeding has significant associated morbidity and cost. 4 Use of anticoagulants is a contributor to GI bleeding and may affect its management. 5, 6 In addition, antiplatelets account for 14.5% of cases of UGI bleeding. 7 In a prospective study involving 18,820 hospital admissions, 376 were related to aspirin, clopidogrel, or warfarin, and the majority of those admissions were due to GI bleeding. 8 Furthermore, low-dose aspirin and antithrombotic drugs increase UGI and LGI bleeding-related morbidity. 9, 10 Antiplatelets and anticoagulants are commonly used for the treatment and prophylaxis of vascular diseases. A summary of their mechanism and duration of action and mode of reversal is shown in Table 1 . Although knowledge about the risk of GI bleeding, its treatment and prevention in patients on anticoagulants and/or antiplatelets has expanded, many questions remain unanswered.
We performed a systemic review of the medical literature on GI bleeding in the setting of anticoagulation and/or antiplatelet therapy using PubMed database. Our search was based on the keywords ''gastrointestinal bleeding'' or ''gastrointestinal hemorrhage'' in combination with ''aspirin,'' ''clopidogrel,'' ''heparin,'' ''low molecular weight heparin,'' ''warfarin,'' ''antithrombotic,'' ''anticoagulant,'' or ''antiplatelet.'' The search covered publications between 1978 and February 2007. The search included original and review articles and their bibliographies. Estimates of risks and therapeutic outcomes were obtained from randomized trials, whereas risk factor identification was gathered from cross-control and prospective cohort studies.
OCCULT GI BLEEDING AND IRON-DEFICIENCY ANEMIA IN PATIENTS ON ANTICOAGULANT AND/OR ANTIPLATELET THERAPY
Fecal occult blood testing (FOBT) is used to screen for GI cancers and investigate iron-deficiency anemia. 12 Population studies found a rate of positive FOBT of 1.7% to 4.4%. 13, 14 One study showed a higher rate reaching 16%. 15 The effect of anticoagulants and antiplatelets on occult GI blood loss has been investigated. [16] [17] [18] A study on 256 patients on warfarin or heparin found that 12% of the 175 patients who completed the study protocol had positive FOBT compared with 3% of controls. 17 Of 21 patients with positive tests, 16 underwent diagnostic evaluation revealing new findings in all but one. Four had colon cancer. There was no difference in the rate of lesions between the heparin and warfarin groups.
Bini et al 19 studied the positive predictive value of FOBT in persons taking warfarin. Lesions consistent with occult bleeding were identified in 59.0% of patients on warfarin and 53.8% of controls (P = 0.27). More lesions were identified by colonoscopy in the warfarin group (36.2% vs. 25.7%, P = 0.02), but there was no difference in the frequency of UGI tract lesions. Hence, warfarin use did not seem to decrease the positive predictive value of FOBT.
Greenberg et al 16 conducted a prospective crossover study using Hemmocult II and HemoQuant tests on 100 participants taking aspirin (81 or 325 mg), warfarin, or none. Fecal blood loss was not increased by warfarin and was not related to the degree of anticoagulation. Aspirin caused a small dose-dependent increase in fecal blood loss that was not sufficient to interfere with FOBT. 16 Another study on 40 healthy volunteers given 30 to 325 mg of aspirin or placebo confirmed the results. 20 Finally, in a study on 193 veterans who were referred for evaluation of positive FOBT, the chance of finding colonic pathology was not affected by the intake of low or high-dose aspirin; however, no UGI endoscopy was performed on patients with negative colonoscopy. 21 Overall, these studies suggest that aspirin use is not associated with false-positive FOBT.
The use of low-dose aspirin or warfarin or both in 267 patients with myocardial infarction who were followed up for 4 years did not lead to anemia or iron deficiency. 22 Furthermore, a study on 695 out-patients referred for evaluation of iron-deficiency anemia found no difference in the rate of GI malignancies between patients taking and those not taking aspirin or warfarin. 23 In conclusion, the literature suggests that positive FOBT and iron-deficiency anemia may not be attributed to aspirin or warfarin intake, and that use of antiplatelets or anticoagulants does not diminish the positive predictive value of FOBT to find GI pathology. Consequently, the data does not support discontinuation of such drugs before doing FOBT, which is commonly practiced. 19 Finally, patients with positive FOBT or iron-deficiency anemia on antiplatelets/anticoagulants should have a full investigation for sources of blood loss. 16 
GROSS GI BLEEDING IN PATIENTS ON ANTIPLATELETS AND/OR ANTICOAGULANTS

Risk and Predictors
The risk of gross GI bleeding associated with use of antiplatelets and anticoagulants depends on the specific drug(s), the dose, the anticipated duration of administration, and the indication. Moreover, the patient's age, sex, comorbid conditions, and past medical history are important. Patient and drug-related factors thought to increase the risk of GI bleeding are listed in Table 2 .
Aspirin
Aspirin use increases the risk of GI bleeding, but it is not clear if this is dose-dependent. The relative risk of major UGI bleeding increases from 1.8 with 100 mg to 7.6 with 500 mg of aspirin. 24 However, a meta-analysis of randomized controlled trials of low-dose aspirin showed that it increases the risk of GI bleeding about 2-fold, with no difference between ''lower'' (76 to 162.5 mg daily) and ''higher'' (>162.5 to 325 mg daily) low-dose aspirin. Whether old age is a risk factor for GI bleeding in patients on low-dose aspirin is unclear. The yearly risk of ''UGI complication'' in young patients with no history of UGI pathology is around 0.2%. It goes up to 12% in patients older than 80 with history of complicated ulcer. 26 In addition, a study using 100-mg aspirin/d in healthy individuals over 70 showed that the risk of bleeding is 3% per year. However, there was no control group younger than 70. 27 Moreover, Laine 28 suggests that low-dose aspirin doubles the risk of GI bleeding irrespective of age, and that baseline absolute risk in the elderly is high.
25
The impact of sex on the risk of GI bleeding on aspirin is unknown. In women, 100 mg every other day increased the risk of transfusion requiring GI bleeding 1.4-fold compared with placebo over 10 years. 29 In the Framingham study, women with atrial fibrillation given aspirin were as likely to have GI bleeding as men, although the number of patients was small. 30 In a study on 991 patients on aspirin followed-up for 2 years, 21% of cases of UGI bleeding occurred within a month and 45% within 4 months of starting therapy. 31 However, acute aspirin administration doubles the risk of bleeding in patients undergoing coronary artery bypass surgery during the index hospitalization.
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A case-controlled study involving 368 patients taking low-dose aspirin found that history of GI bleeding or ulcer disease increased the risk of UGI bleeding 6.5 and 2.1-fold, respectively.
33 Furthermore, concomitant nonsteroidal anti-inflammatory drug or corticosteroid use probably increases the risk of GI bleeding in aspirin users. [34] [35] [36] [37] [38] Finally, in a large case-controlled study involving 1121 patients with bleeding peptic ulcer, the odds ratio for bleeding associated with heart failure and diabetes were 5.9 and 3.1, respectively.
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Clopidogrel
Compared with placebo, the risk of GI bleeding associated with clopidogrel use is not known. A lower risk of UGI bleeding associated with use of clopidogrel as compared with aspirin has been suggested. 25 ,40,41 However, clopidogrel use clearly increases the risk of GI bleeding in patients with history of dyspepsia, peptic ulcer, or GI bleed.
7,42
Anticoagulants
In a study on stroke prevention in patients with atrial fibrillation, low-intensity anticoagulation with warfarin [International Normalized Ratio (INR) of 1.2 to 1.5] did not increase the risk of GI bleeding. 43 However, the risk increases dramatically with the intensity of anticoagulation particularly at INRZ4.5. 44, 45 Old age is an independent risk factor for major bleeding on warfarin. 44, 46 In elderly patients receiving warfarin for atrial fibrillation, independent predictors of bleeding (GI and non-GI) are old age, female sex, diabetes, and anemia. 46 Intravenous heparin given for secondary stroke prevention had a greater morbidity-ratio estimate of GI bleeding than warfarin or aspirin. 47 Similarly, subcutaneous administration of heparin at 5000 to 12,500 U twice daily seems to be associated with a substantial risk of extracranial bleeding of 0.4% to 1.4% per 2 weeks. 48 The average daily frequency of fatal and major bleeding during heparin therapy were 0.05% and 0.8%, and bleeding affected the GI tract in 27% of cases. 49 The use of low molecular weight heparin is associated with a markedly lower risk of GI bleeding. 49, 50 Predictors of bleeding on heparin include female sex, intensity of anticoagulation, old age, concomitant aspirin use, presence of comorbid conditions, and alcohol abuse. 44, 49, 50 Combination Therapy
A recent large case-control study found that combining any 2 antiplatelet or anticoagulant medications substantially increases the risk of serious upper GI bleeding compared with monotherapy. 51 In the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) and the clopidogrel in unstable angina to prevent recurrent events (CURE) studies, combining aspirin and clopidogrel substantially increased the risk of GI bleeding. 25, 52, 53 Moreover, in patients with mechanical valves, the addition of aspirin to warfarin doubled the risk of GI bleeding compared with the addition of placebo. 54 When the target INR is lowered, low-dose aspirin does not seem to alter the rate of GI bleeding when added to warfarin. 55 Of interest are patients with acute coronary syndrome who receive a combination of antiplatelet, antithrombotic, and thrombolytic drugs. In 2 retrospective studies, the inhospital risk of UGI bleeding was 0.6% and 0.7% 56 and this risk increased in the first year of follow-up. 57 Home but not in-hospital intake of antiplatelets was a predictor of inhospital UGI bleeding.
For patients with acute coronary syndrome who require drug eluting stents (DES), dual antiplatelet therapy (aspirin and a thienopyridine) was initially recommended for a period of 3 to 12 months. [58] [59] [60] However, late stent thrombosis was later reported to occur years after DES implantation, and was thought to be related to cessation of clopidgrel. [61] [62] [63] [64] This has prompted some investigators to suggest that patients with DES may require long term and possibly life long dual antiplatelet therapy, and that further studies are required to determine the optimal duration of such therapy. 62, 63 The risk of GI bleeding within the first 30 days of dual antiplatelet therapy is 1.3%, and increases 
dramatically to 12% in high-risk patients with previous GI bleeding. 65, 66 Prolonging the duration of treatment or increasing the dose of antiplatelet drugs amplifies the risk of GI bleeding as shown by the CURE study. 67 In those who require long-term dual antiplatelet therapy, lowering the dose of aspirin (75 to 162 mg/d) may reduce the risk of bleeding complications. 68 In patients requiring triple therapy (dual antiplatelet medications and an anticoagulant drug), bleeding complications (GI and non-GI) ranged between 9.2% and 20% at 30 days of treatment. [69] [70] [71] Major bleeding events requiring blood transfusions or surgical intervention occurred in 1% to 15% of patients. [69] [70] [71] Lip and Karpha 69 reported that all major bleeding complications were GI, and were associated with age >75 years, overtherapeutic INR, and identifiable lesions in the GI tract.
In conclusion, it might be useful to divide patients taking antiplatelet and/or anticoagulant drugs into groups at low, intermediate, or high-risk for GI bleeding on the basis of the number of risk factors and their importance. Two such indices have been formulated and validated prospectively for the risk of major bleeding (GI and non-GI) in patients on warfarin therapy.
46,72
Management
Clinical risk stratification of bleeding patients might help in recognizing those at risk for adverse outcome and need for urgent intervention and treatment. 73 Use of aspirin, clopidogrel, or warfarin was associated with longer duration of hospitalization and increased need for transfusion in UGI bleeders. 10 In patients with LGI bleeding, aspirin use was an independent predictor of severe hemorrhage. 9 
Site of GI Bleeding in Anticoagulated Patients
Most studies on etiology of GI bleeding in anticoagulated patients are retrospective, involve small number of patients, or originate from single centers. In those studies, a bleeding site was identified in more than 80% of patients with acute GI bleeding on anticoagulants, [74] [75] [76] and gastroduodenal ulcers and erosions accounted for more than 50% of lesions in those with UGI bleeding. 74, [77] [78] [79] A prospective noncontrolled study of 18 episodes of bleeding in 17 patients using warfarin or heparin found that 44% of patients had duodenal ulcers. 80 This was confirmed by 2 controlled studies that found that peptic ulcer was the cause of UGI bleeding in 45% of patients. 74, 79 Erosive esophagitis is also an important cause of GI bleeding in patients taking low-dose aspirin or antithrombotic agents. 78 No studies addressed specifically the source of LGI bleeding in patients using aspirin, heparin, or warfarin. Of patients presenting with GI bleeding (unspecified as lower or upper), 25% to 33% were thought to have colonic pathology with polyps, diverticulae, and angiodysplasia being the most common. 75, 76 Patients with supratherapeutic INR have mucosal abnormalities in the UGI and LGI tracts similar to those in patients with a therapeutic INR, except for a higher prevalence of gastritis. 75 In 17% to 29% of patients with GI bleeding on antiplatelets or anticoagulants, no mucosal abnormality is found on endoscopic investigation. 74, 78, 79 The role of capsule endoscopy and/or enteroscopy in such patients is not known. A prospective nonrandomized study that examined small bowel pathology in patients with obscure GI bleeding using capsule endoscopy found that antiplatelets/anticoagulants use had no impact on the chance of finding mucosal pathology. 81 
Discontinuation of Anticoagulants and Reversal of Anticoagulation
In patients with clinically significant GI bleeding, continued administration of antiplatelets or anticoagulants is associated with an extremely high risk of continued or subsequent bleeding. 82, 83 It is not clear, however, how long these drugs should be discontinued, whether reversal of anticoagulation should be partial or complete, and how best to achieve such a reversal. Usually, the decision is based on a balance between the risk of thromboembolism and that of continued or recurrent bleeding. Hence, it might be helpful to stratify patients with clinically significant GI bleeding into high-risk or low-risk for thromboembolism if anticoagulation is to be reversed partially or completely. According to The American Society of Gastrointestinal Endoscopy (ASGE) guidelines, high-risk patients are those with deep vein thrombosis or arterial embolism within the past 6 months, valvular heart disease with atrial fibrillation, mitral mechanical valve, any mechanical valve with a previous thromboembolic event, atrial fibrillation with a previous cardioembolic event or a risk factor for stroke, recurrent venous or arterial thromboembolism, or any hypercoagulable state with at least one thromboembolic event. Conversely, low-risk patients are those with isolated venous or arterial thromboembolic event older than 6 months, atrial fibrillation without valvular disease, aortic mechanical valve, or a bioprosthetic valve. 84 Complete withdrawal of anticoagulation is associated with a low risk of thromboembolic events even in patients with prosthetic valves. 85 However, most studies involve a small number of patients and are not randomized. In one study on 28 patients with major bleeding, withholding warfarin for a mean of 15 days and reversal of anticoagulation was associated with no embolic complications. 86 In another study on 21 patients with prosthetic valves, withholding warfarin for a mean of 3 days was associated with only one thromboembolic event over a period of 8 months. 87 In patients with atrial fibrillation whose anticoagulation was withdrawn for endoscopic procedures, the risk of stroke was 1.06% per procedure. 88 Factors associated with increased risk were age above 80 years, history of stroke, hypertension, hyperlipidemia, and family history of vascular disease. 89 Three controlled retrospective studies have addressed the management of GI bleeding in patients using antiplatelets and/or anticoagulants. 74, 75, 79 In all, partial reversal of anticoagulation to an INR of 1.5 to 2.5 using fresh frozen plasma and/or vitamin K was performed. Upper and lower GI diagnostic and therapeutic GI procedures were done a mean of 1 to 3.7 days after admission without complete reversal of anticoagulation. Mortality, hospital stay, and number of transfused units in patients using warfarin were similar to controls. A supratherapeutic INR on admission did not have a negative impact on major clinical outcomes. 75 In patients using warfarin, early endoscopy might reveal lesions requiring endoscopic hemostasis and could lead to the diagnosis of previously unrecognized lesions. 79 In those with bleeding ulcers, endoscopic hemostasis after partial correction of the INR to 1.5 to 2.5 was not associated with increased risk of uncontrollable bleeding or emergency surgery. Overall mortality rate was low and was similar to that in patients not receiving anticoagulants. 79 A retrospective controlled study by Wolf et al 6 suggests that performing therapeutic endoscopy in mildly to moderately anticoagulated patients with UGI bleeding is safe and is not associated with increased risk of rebleeding.
For nonbleeding or mildly bleeding patients with excessive anticoagulation (INR>6), oral vitamin k 1 (1 to 5 mg) is effective in restoring the INR to the therapeutic range and is safe. 89, 90 For patients with life-threatening bleeding (GI and non-GI), emergency reversal of anticoagulation with recombinant factor VIIa (1.2 mg or 20 to 106 mg/kg) is effective in stopping or decreasing bleeding within 2 hours of administration. 91, 92 In addition, Baglin et al 85 recommend administration of intravenous rather than oral vitamin K (5 to 10 mg) if reversal is to be sustained. Similarly, prothrombin complex concentrate (PCC) is effective for the immediate reversal of anticoagulation in patients with lifethreatening hemorrhage. 93, 94 Coadministration of vitamin K is essential for sustaining the reversal. 78, 90 When oral vitamin K is used for warfarin reversal, the injectable formula of vitamin K is preferable to tablets because of its flexible dosing. 82 Thrombotic complications have been described after PCC administration, and anaphylactoid or fatal reactions to vitamin K may occur after administration of small doses intravenously. 93, 95 In addition, reports on the use of PCC and recombinant factor VII specifically in GI bleeding have been limited to case reports or small numbers of patients. Therefore, the safety, efficacy, and optimal dose of recombinant factor VII, PCC, and vitamin K in patients with GI bleeding need to be determined in further studies.
No studies have compared complete and partial reversal of anticoagulation in patients with GI bleeding on basis of the risk for thromboembolic disease. We would like to suggest an approach that takes into account the risk of thromboembolic disease (Fig. 1) . 96, 97 The suggested algorithm needs validation in prospective studies.
PROPHYLAXIS
Gastroduodenal ulcers or erosions and erosive esophagitis account for 50% to 60% of lesions responsible for GI bleeding in patients on antiplatelets or anticoagulants. [75] [76] [77] [78] [79] [80] Most studies on prophylaxis against GI bleeding have addressed the role of acid suppression and/or Helicobacter pylori eradication in patients known to have or are likely to have acid-related gastroduodenal injury.
Ranitidine reduces the risk of rebleeding in patients with ulcers. 98 Furthermore, proton-pump inhibitors (PPIs) reduce the risk of bleeding in patients who had a bleeding episode from an acid-related lesion despite continued intake of antiplatelets. 7, 99 In patients with UGI bleeding on aspirin, H. pylori infection is an independent risk factor. 100 Moreover, H. pylori eradication is equivalent to maintenance therapy with omeprazole in reducing the risk of recurrent bleeding on aspirin. 101 In patients at low to moderate-risk of developing gastroduodenal injury, low-dose aspirin seems to be equivalent to clopidogrel, 102 but in those with documented aspirin-related ulcer bleeding, the risk of rebleeding is lower on aspirin plus a PPI than on clopidogrel alone. 103 The literature, therefore, supports administration of a PPI and eradication of H. pylori infection in patients with history of upper GI ulceration or bleeding who need to take antiplatelets. 42, 104, 105 In elderly patients on aspirin, such therapy reduces the prevalence of ulcers, but its effect on bleeding risk is unclear. 106 What to do in high-risk patients who have no history of peptic disease is unclear. Using the lowest effective dose of aspirin, 107 lowering the intensity of anticoagulation, and avoiding nonsteroidal anti-inflammatory drugs, corticosteroids, and combination therapy may reduce the risk of bleeding, 49, 108 but need validation by randomized controlled studies. Kimmey 109 proposes that the indication for PPI in patients using aspirin increases as the number of risk factors for GI bleeding increases, which needs validation in prospective trials.
Most GI bleeding episodes on antiplatelets or anticoagulants occur within the first year of therapy. It is interesting to speculate if performing FOBT in asymptomatic high-risk patients might have a role in the management. 110 
